Risk factors for the development of epilepsy in patients with brain metastasis.
Current guidelines do not recommend primary prophylactic anti-epileptic drug therapy for patients with brain metastases (BM). Yet, subgroups of patients at high seizure risk might still benefit from prophylaxis. We identified 799 patients diagnosed with BM by retrospective screening of our electronic chart system. Candidate risk factors for the development of epilepsy were tested by univariate and multivariate Cox regression models. Epilepsy was diagnosed in 226 of 799 patients (28%). Risk factors for epilepsy in non-operated patients were single BM (p=0.002, hazard ratio (HR) 3.2, 95% confidence interval (CI) 1.5-6.6) and detection of tumoral hemorrhage (p= 0.008, HR 2.5, 95% CI 1.3-4.9). Pre-operative seizures occurred predominantly in patients with supratentorial BM (p=0.003, HR 20.78, 95% CI 2.8-153.4) and lung cancer (p= 0.022; HR 2.0, 95% CI 1.1-3.6). Post-operative seizures were associated with supratentorial localization (p=0.017, HR 5.8, 95% CI 1.4-24.3), incomplete resection (p=0.005, HR 4.6, 95% CI 1.6-13.1), and by trend for multiple brain surgeries (p=0.095, HR 1.9, 95%CI 0.9-4.0). These risk factors were integrated into a predictive score model for post-operative epilepsy (score sum 0-8). A gradual increase of seizure rates along with higher sum score was confirmed post-hoc (score 0, no seizures; score 8, 48% seizures). Receiver-operating characteristic analysis supported diagnostic accuracy (p=0.00001, AUC=0.75). Here we have defined risk profiles for the development of BM-related epilepsy and derived a score which might help to estimate the risk of post-operative seizures and identify individuals at risk who might benefit from primary prophylactic anti-epileptic drug therapy.